Patents Assigned to The University of Chicago
  • Publication number: 20250052960
    Abstract: Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
    Type: Application
    Filed: August 8, 2024
    Publication date: February 13, 2025
    Applicant: The University of Chicago
    Inventors: Jiwoong Park, Hanyu Hong, Myungjae Lee
  • Patent number: 12216121
    Abstract: Described herein are nucleic acid molecules and complexes useful for spatiotemporally mapping intra-endosmal thiol disulphide exchange. Aspects of the disclosure relate to a composition comprising a first nucleic acid conjugated to a normalization moiety; and a second nucleic acid conjugated to a catalytic substrate; wherein reaction of the substrate with a catalyst produces a detectable product; and wherein the first and second nucleic acids are complementary or substantially complementary. Further aspects relate to a composition comprising: a first nucleic acid conjugated to a normalization moiety and to a catalytic substrate; and a second nucleic acid; wherein reaction of the substrate with a catalyst produces a detectable product; and wherein the first and second nucleic acids are complementary or substantially complementary.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 4, 2025
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Yamuna Krishnan, Krishna Dan, Aneesh T. Veetil, Kasturi Chakraborty
  • Patent number: 12210935
    Abstract: Technologies for resource-efficient quantum error correction are disclosed. A quantum computer may include physical gate qubits, capable of general quantum gate operations such as single-qubit operations and nearest-neighbor two-qubit operations. Each physical qubit gate may be controllably coupled to a quantum memory. The quantum memory may have a lower per-gate error rate than the physical qubit gates as well as a lower per-qubit cost. Because errors accrue at a lower rate in the quantum memory, the physical gate qubits may be able to perform error correction for a large number of logical qubits in the quantum memory, even if the physical gate qubits have an error rate relatively close to an error threshold.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: January 28, 2025
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: David Schuster, Srivatsan Chakram
  • Patent number: 12209143
    Abstract: The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: January 28, 2025
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Raymond E. Moellering, Jeffrey E. Montgomery
  • Publication number: 20250026814
    Abstract: Here, the inventors report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally. RBD-binding antibodies could be categorized into 3 distinct classes based on their binding profiles against RBD mutant constructs. The inventors identified VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, this study identifies that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.
    Type: Application
    Filed: November 16, 2022
    Publication date: January 23, 2025
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Patrick WILSON, Siriruk CHANGROB, Haley DUGAN, Christopher STAMPER
  • Publication number: 20250025542
    Abstract: Aspects of the present disclosure are directed to methods and compositions for generation of antigen-specific regulatory T cells. Certain aspects relate to methods and compositions for generating tolerogenic antigen presenting cells, including tolerogenic dendritic cells. The present disclosure includes compositions, including nanocarrier compositions, comprising TLR agonists, and immunosuppressive agents and optionally an antigen. Also disclosed are methods for use of such compositions in generation of tolerogenic antigen presenting cells and treatment of certain conditions, including autoimmune and inflammatory conditions.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 23, 2025
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Aaron ESSER-KAHN, Peter DEAK
  • Publication number: 20250018038
    Abstract: Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.
    Type: Application
    Filed: October 6, 2022
    Publication date: January 16, 2025
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Anthony KOSSIAKOFF, Annika SÄÄF, Marcin URA, Somnath MUKHERJEE
  • Publication number: 20250017898
    Abstract: Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.
    Type: Application
    Filed: June 11, 2024
    Publication date: January 16, 2025
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Raymond MOELLERING, John COUKOS, Gihoon LEE, Jae Won CHANG, Gokhan MUTLU
  • Patent number: 12186402
    Abstract: Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.
    Type: Grant
    Filed: April 19, 2023
    Date of Patent: January 7, 2025
    Assignee: The University of Chicago
    Inventors: Jeffrey A. Hubbell, Ruyi Wang, D. Scott Wilson, Cathryn R. Nagler, Catherine Plunkett
  • Patent number: 12188084
    Abstract: Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: January 7, 2025
    Assignee: The University of Chicago
    Inventors: Chuan He, Boxuan Simen Zhao, Pradnya Narkhede, Chang Liu, Xiaolong Cui
  • Patent number: 12180267
    Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: December 31, 2024
    Assignee: The University of Chicago
    Inventors: Patrick Wilson, Yaoqing Chen, Haley L. Dugan
  • Patent number: 12174225
    Abstract: Methods and systems are disclosed for sensing an environment electric field. In one exemplary implementation, a method includes disposing a sensor in the environment, wherein the sensor comprising a crystalline lattice and at least one optically-active defect in the crystalline lattice; pre-exciting the crystalline lattice to prepare at least one defect in a first charge state using a first optical beam at a first optical wavelength; converting at least one defect from the first charge state to a second charge state using a second optical beam at a second optical wavelength; monitoring a characteristics of photoluminescence emitted from the defect during or after the conversion of the at least one defect from the first charge state to the second charge state; and determining a characteristics of the electric field in the environment according to the monitored characteristics of the photoluminescence.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: December 24, 2024
    Assignee: The University of Chicago
    Inventors: Gary Wolfowicz, Samuel James Whiteley, David Daniel Awschalom
  • Publication number: 20240417802
    Abstract: The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method for treating cancer in a subject comprising administering to the subject an immunotherapy after a biological sample from the subject has been analyzed for membrane-localized antigens (mAg).
    Type: Application
    Filed: October 14, 2022
    Publication date: December 19, 2024
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Jeffrey HUBBELL, Priscilla BRIQUEZ, Zoe GOLDBERGER, Sylvie HAUERT
  • Publication number: 20240415851
    Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
    Type: Application
    Filed: March 14, 2024
    Publication date: December 19, 2024
    Applicants: The University of Chicago, The United States of America, as Represented by the Secretary, Department of Health and Human, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Julian SOLWAY, Nickolai DULIN, Marsha ROSNER, Gokhan MUTLU, Diane LUCI, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN
  • Publication number: 20240408138
    Abstract: Aspects of the present disclosure are directed to INCENP-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such INCENP-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using INCENP-targeting polypeptides.
    Type: Application
    Filed: October 6, 2022
    Publication date: December 12, 2024
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Anthony KOSSIAKOFF, Annika SÄÄF, Marcin URA, Somnath MUKHERJEE
  • Publication number: 20240410901
    Abstract: The current disclosure describes light switchable actin binding protein (ABP) built from a photosensitive protein and an ABP. This is accomplished by creating an ABP that is caged and has a weak affinity to actin in the dark and uncaged with a strong affinity for actin in the light. These light-switchable polypeptides can recruit other actin binding proteins of interest to actin filaments spatiotemporally and reversibly. Aspects of the disclosure relate to polypeptides that are useful for labeling actin fibers. Accordingly, the disclosure relates to a polypeptide comprising the amino acid sequence: AXXIXXXA(M)nGVADLIKKFE(X?)n? (SEQ ID NO:1) or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:1, wherein X is any amino acid, n and n? are each independently selected from 0 and 1, and X? is equal to SISKEE.
    Type: Application
    Filed: October 7, 2022
    Publication date: December 12, 2024
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Tobin SOSNICK, Kourtney KROLL, Ronald ROCK, Alexander FRENCH
  • Publication number: 20240398785
    Abstract: The present disclosure provides methods and compositions for inducing trained immunity, preventing infections, improving immune responses, modulating the activity of at least one protein in the BCL family of proteins, increasing the efficacy of a vaccine, and reducing the risk of a secondary tumor in a subject diagnosed with a primary cancer.
    Type: Application
    Filed: May 30, 2024
    Publication date: December 5, 2024
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Aaron ESSER-KAHN, Hannah KNIGHT, Jainu AJIT
  • Publication number: 20240382591
    Abstract: The current disclosure provides for techniques and approaches for the generation of autologous mutant neoantigen-specific, TCR-engineered T cells used for adoptive transfer in treatment of cancer patients. Also provided are surrogate cancer cells, which is a personalized cell system that can be used for vaccination and TCR discovery in cancer patients.
    Type: Application
    Filed: September 21, 2022
    Publication date: November 21, 2024
    Applicants: THE UNIVERSITY OF CHICAGO, CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
    Inventors: Hans SCHREIBER, Matthias LEISEGANG, Steven Patrick WOLF, Vasiliki ANASTASOPOULOU, Karin SCHREIBER, Michael BISHOP, Amittha WICKREMA
  • Patent number: 12145991
    Abstract: A pharmaceutical composition generally includes a therapeutic antibody, or fragment thereof, and a pharmaceutically acceptable carrier. The therapeutic antibody specifically binds to a target peptide that mediates pain in a subject. The composition may be administered to a subject experiencing pain to at least partially alleviate the pain.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: November 19, 2024
    Assignees: UNM Rainforest Innovations, Loyola University of Chicago
    Inventors: Karin Westlund High, Ravi Venkata Durvasula, Adinarayana Kunamneni
  • Patent number: 12138320
    Abstract: Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: November 12, 2024
    Assignee: The University of Chicago
    Inventors: Raymond E. Moellering, Jae Won Chang